中国体内放射性药物的现状与展望

    PRESENT STATUS AND PROSPECT IN VIVO RADIOPHARMACEUTICALS IN CHINA

    • 摘要: 本文扼要介绍我国十年来体内放射性药物的进展。诊断和治疗用体内放射性药物的发展很迅速,已有反应堆生产与加速器生产的系列医用放射性核素及放射性药物,尤其是~(99m)Tc标记的脑、心灌注显像剂、放射免疫显像剂等。本文还对今后的发展提出一些建议与展望。

       

      Abstract: The radiopharmaceutical chemistry is an important part in applied radio-chemistry. In this paper is given a review of in vivo radiopharmaceuticals in our country in recent years. It should be pointed out that in vivo radiopharmaceuticals including diagnostic and therapeutic have enjoyed rapid development. Recently, a series of reactor and cyclotron produced medical radionuclides and their radiopharmaceuticals, especially new 99mTc labelled brain perfusion imaging agents 99mTc-dl-HMPAO, 99mTc-ECD, myocardial perfusion imaging agents 99mTc-CPI and MIBI, radioimmunoimaging agents etc. have heen reported. Furthermore, R and D suggestions and future trends are discussed.

       

    /

    返回文章
    返回